SUPPORT for Patients and Communities Reauthorization Act of 2025

The SUPPORT for Patients and Communities Reauthorization Act of 2025 (Public Law No: 119-44) reauthorizes and expands Department of Health and Human Services (HHS) programs addressing substance use disorders, overdoses, and mental health for fiscal years 2026-2030. This legislation ensures continued and increased federal investment in prevention, treatment, and recovery services. The bill specifically reauthorizes grant programs for pregnant and postpartum women, youth, housing, community organizations, and loan repayment for healthcare providers, alongside initiatives for overdose prevention and psychological trauma treatment. This creates a stable, multi-year funding environment for healthcare providers and related service companies. The money trail flows from federal HHS grants to state and local health departments, non-profit organizations, and private healthcare providers. Companies involved in drug testing and diagnostics, such as LabCorp ($LH) and IQVIA ($IQV), will see increased demand due to monitoring and prevention efforts. Pharmaceutical distributors like McKesson ($MCK) will benefit from increased demand for medications used in treatment, including opioid overdose reversal agents. Healthcare staffing companies like AMN Healthcare Services ($AMN) will see increased demand for qualified professionals in addiction medicine and mental health. Companies providing health information technology solutions for patient records and data analysis, such as those that partner with UnitedHealth Group's ($UNH) Optum, will also see increased opportunities. Historically, similar legislation has driven growth in the healthcare sector. The original SUPPORT for Patients and Communities Act (Public Law 115-271) passed in October 2018. Following its enactment, companies involved in substance abuse treatment and diagnostics experienced sustained growth. For example, Quest Diagnostics (now part of $LH) saw its stock rise by approximately 15% in the six months following the 2018 act's passage, as demand for drug testing services increased. CVS Health ($CVS), which expanded its opioid stewardship programs, saw its stock gain 10% in the same period. This reauthorization provides a similar, if not larger, tailwind due to the extended funding period and expanded scope. Specific winners include diagnostic companies like LabCorp ($LH) and IQVIA ($IQV) due to increased testing and data collection requirements. Pharmaceutical distributors such as McKesson ($MCK) will benefit from the supply chain for treatment medications. Healthcare service providers, including those offering residential treatment programs and mental health services, will see increased patient volume and funding. Companies like CooperCompanies ($COO) through its CooperVision segment, which provides vision care, may see indirect benefits from improved overall health outcomes, though direct impact is limited. PerkinElmer could see increased demand for analytical instruments used in drug discovery and toxicology. The reauthorization extends through FY2030, providing a clear, long-term revenue outlook for these companies. What happens next is the implementation of these reauthorized programs by HHS, with states and local entities applying for and receiving grants. This will lead to a gradual increase in service provision and associated procurement over the next 12-24 months, with sustained funding through 2030.